CD30 is a transmembrane cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Mature CD30 has a molecular mass of 120 kDa and is derived from a 90 kDa precursor protein (de Bruin, 1995). The extracellular domain of CD30 is homologous to that of TNF receptor superfamily members, whereas there is no homology in teh cytoplasmic domain, suggesting major differences in signaling mechanisms (Falini, 1995). CD30 expression is found on Hodgkin and Reed-Sternberg (H-RS) cells, and on activated B and T lymphocytes (de Bruin, 1995). The antibody from the Ber-H2 hybridoma cell line was included in the Fourth International Workshop on Human Leukocyte Differentiation Antigens and was found to belong to the CD30 cluster (Schwarting, 1989).

Antibody recognizes Human CD30 antigen.

Co-cell line established from a human with Hodgkin′s disease of T-cell lineage.

Milli-Mark Anti-CD30-FITC Antibody, clone Ber-H2 detects level of CD30 & has been published & validated for use in FC.

Research Category
Inflammation & Immunology

Research Sub Category
Immunoglobulins & Immunology

Evaluated by flow cytometry using Jurkat cells

120 kDa (de Bruin, 1995)

Protein A purified

Purified Mouse monoclonal IgG1 conjugated to FITC in 0.05M Tris-HCl buffer with 1% BSA, Sodium Azide at 0.097% at pH 7.2.

Maintain refrigerated at 2-8°C protected from light in undiluted aliquots for up to 6 months from date of receipt.

Control
Jurkat cells

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

MILLI-MARK is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.